| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Close more deals with Winmo. Our advertising database gives you accurate, in-depth profiles of national advertisers and decision-makers.
A Cybersecurity company focused on preventing cyber attacks.
We offer the first marketing automation platform for medical practices. We syndicate great reviews and perfect profiles to the web’s top healthcare sites.
Strategic Information Group is a Cardiff By The Sea, CA-based company in the Software and Internet sector.